Tonix Pharmaceuticals Holding Stock Performance
| TNXP Stock | USD 15.00 1.36 9.97% |
The entity has a beta of -5.39, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Tonix Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Tonix Pharmaceuticals is expected to outperform it. At this point, Tonix Pharmaceuticals has a negative expected return of -0.0268%. Please make sure to validate Tonix Pharmaceuticals' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Tonix Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Tonix Pharmaceuticals Holding has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Tonix Pharmaceuticals is not utilizing all of its potentials. The recent stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 120.5 M |
Tonix |
Tonix Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 3,339 in Tonix Pharmaceuticals Holding on December 17, 2024 and sell it today you would lose (1,839) from holding Tonix Pharmaceuticals Holding or give up 55.08% of portfolio value over 90 days. Tonix Pharmaceuticals Holding is currently does not generate positive expected returns and assumes 15.7157% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Tonix, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tonix Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tonix Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tonix Pharmaceuticals Holding, and traders can use it to determine the average amount a Tonix Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0017
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TNXP |
Estimated Market Risk
| 15.72 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Tonix Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tonix Pharmaceuticals by adding Tonix Pharmaceuticals to a well-diversified portfolio.
Tonix Pharmaceuticals Fundamentals Growth
Tonix Stock prices reflect investors' perceptions of the future prospects and financial health of Tonix Pharmaceuticals, and Tonix Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tonix Stock performance.
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.44 | ||||
| Operating Margin | (5.51) % | ||||
| Current Valuation | 64.32 M | ||||
| Shares Outstanding | 5.59 M | ||||
| Price To Earning | (0.69) X | ||||
| Price To Book | 1.13 X | ||||
| Price To Sales | 7.43 X | ||||
| Revenue | 7.77 M | ||||
| EBITDA | (114.09 M) | ||||
| Cash And Equivalents | 145.48 M | ||||
| Cash Per Share | 3.38 X | ||||
| Total Debt | 9.81 M | ||||
| Debt To Equity | 0 % | ||||
| Book Value Per Share | 47.68 X | ||||
| Cash Flow From Operations | (102 M) | ||||
| Earnings Per Share | (8,039) X | ||||
| Total Asset | 154.46 M | ||||
| Retained Earnings | (600.66 M) | ||||
| Current Asset | 46.36 M | ||||
| Current Liabilities | 6.65 M | ||||
About Tonix Pharmaceuticals Performance
Assessing Tonix Pharmaceuticals' fundamental ratios provides investors with valuable insights into Tonix Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Tonix Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. The company was founded in 2007 and is headquartered in Chatham, New Jersey. Tonix Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.Things to note about Tonix Pharmaceuticals performance evaluation
Checking the ongoing alerts about Tonix Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tonix Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tonix Pharmaceuticals generated a negative expected return over the last 90 days | |
| Tonix Pharmaceuticals has high historical volatility and very poor performance | |
| Tonix Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7.77 M. Net Loss for the year was (116.66 M) with profit before overhead, payroll, taxes, and interest of 2.34 M. | |
| Tonix Pharmaceuticals Holding currently holds about 145.48 M in cash with (102 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38. | |
| Tonix Pharmaceuticals has a very weak financial position based on the latest SEC disclosures |
- Analyzing Tonix Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tonix Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Tonix Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tonix Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tonix Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tonix Pharmaceuticals' stock. These opinions can provide insight into Tonix Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tonix Stock Analysis
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.